Cue Biopharma Inc (CUE)
1.50
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
1.57
+0.07
(+4.67%)
After-Hours: 20:00
Cue Biopharma Research and Development Expense (Quarterly): 9.53M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.53M |
| March 31, 2024 | 10.20M |
| December 31, 2023 | 10.89M |
| September 30, 2023 | 9.874M |
| June 30, 2023 | 10.65M |
| March 31, 2023 | 9.391M |
| December 31, 2022 | 11.33M |
| September 30, 2022 | 7.571M |
| June 30, 2022 | 9.592M |
| March 31, 2022 | 10.08M |
| December 31, 2021 | 11.50M |
| September 30, 2021 | 11.29M |
| June 30, 2021 | 8.762M |
| March 31, 2021 | 9.816M |
| December 31, 2020 | 8.004M |
| September 30, 2020 | 7.517M |
| Date | Value |
|---|---|
| June 30, 2020 | 8.119M |
| March 31, 2020 | 9.906M |
| December 31, 2019 | 6.964M |
| September 30, 2019 | 5.302M |
| June 30, 2019 | 6.867M |
| March 31, 2019 | 8.353M |
| December 31, 2018 | 6.823M |
| September 30, 2018 | 10.31M |
| June 30, 2018 | 5.414M |
| March 31, 2018 | 5.819M |
| December 31, 2017 | 9.019M |
| September 30, 2017 | 4.002M |
| June 30, 2017 | 3.417M |
| March 31, 2017 | 2.461M |
| December 31, 2016 | 2.065M |
| September 30, 2016 | 1.400M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.964M
Minimum
Dec 2019
11.50M
Maximum
Dec 2021
9.526M
Average
9.816M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Arbutus Biopharma Corp | 14.27M |
| GlycoMimetics Inc | 6.286M |
| FibroGen Inc | 34.11M |
| Cidara Therapeutics Inc | 12.43M |